Oncotarget Gives Great News to those with PTC

The nationally peer-reviewed journal Oncotarget is responsible for the resurgence of research on the pathological effects of cancer treatment and cancer diagnosis. Oncotarget firmly and rightly believes that the more hope a patient feels when going through the battle of cancer the greater chance they will survive the ordeal. They have found that many factors contribute to an overall feeling of hope including things to look forward to in the future, family support systems, and religious observance.

Oncotarget routinely examines various programs that manage cancer and pain to review them based on their ability to increase a patient’s quality of life. Check the journal at SCImago Journal & Country Rank.

Oncotarget recently sat down with Dr. Carmelo Nucero to interview him on his breakthrough research concerning papillary thyroid carcinoma. For those who may not know, papillary thyroid carcinoma has long been known to oncologists as the “resistant cancer.” This is due to its ability to develop a resistance to vemurafenib which targets the BRAF gene which is the cause of papillary thyroid carcinoma. This has led to many patients watching as their cancer goes into remission only to be called back into the oncologist office to be told that their cancer is now drug-resistant and incurable.

Dr. Carmelo Nucero was tired of being unable to give them the hope they desired, so he began taking many years to research how to make papillary thyroid carcinoma less resistant to the drug vemurafenib. He was able to find that when vemurafenib was mixed with palbociclib that both drugs became more effective.

What would happen is that the body would begin recognizing vemurafenib as a domestic substance. Once that occurred the two drugs were able to work in harmony and palbociclib promoted stronger cell regeneration of healthy cells while vemurafenib was able to promote more cell elimination for the cancer cells. Learn more about Oncotarget at Eurekalert.org.

Dr. Carmelo Nucero says that the FDA seems favorable the passage treatment since both drugs have Artie been approved previously.

To stay up-to-date on the news regarding Dr. Carmelo Nucero’s research and much more, subscribe to Oncotarget’s podcast which is available on iTunes and the Google play store.

Follow: https://twitter.com/oncotargetjrnl?lang=en

Comments are closed.